ANIP ANI PHARMACEUTICALS INC Insider Trading

Director Walsh Patrick D sells 13,973 shares (28% of holdings) for $1.13M as stock trades below 52-week highs

Patrick Walsh, a director at ANI Pharmaceuticals, sold nearly fourteen thousand shares across two transactions in May, representing roughly a quarter of his direct shareholding and reducing his position from approximately 52,400 to 38,400 shares. The sales occurred at prices slightly below the current trading level, while the stock remains notably below its 52-week high—a period in which ANI has delivered strong fundamentals, including profitable operations, double-digit annual revenue growth, and a stable valuation multiple. This is Walsh's first open-market sales activity at ANI over the filing window, following his earlier acquisition of shares through stock-based compensation. The timing and magnitude of the disposition—liquidating a meaningful stake over consecutive trading days while the company demonstrates solid financial health—merit attention to whether this reflects portfolio rebalancing or a shift in Walsh's confidence in the company's near-term prospects.

ANIP President & CEO Lalwani sells 55,000 shares worth $4.3M; sixth open-market sale in 36 months despite profitable fundamentals.

Nikhil Lalwani, the company's President and CEO, sold a meaningful block of shares representing nearly 14% of his holdings. This is his sixth open-market sale at ANIP within the past three years, continuing a pattern of liquidation activity with no offsetting open-market purchases over the same period. The sale occurred while ANIP is profitable and growing revenue sharply, yet the stock is currently trading well below its 52-week high. His prior sales at this ticker show mixed timing—three of four prior sales with measurable outcomes were well-timed exits (the stock fell afterward), though one sale preceded gains. The insider's track record does not suggest conviction in near-term upside; rather, it shows a consistent pattern of trimming positions regardless of price action or fundamental strength.

CFO Carey Stephen P. sold 7,312 shares at $75.50 avg on 2026-03-05 for $552,031.04

Carey Stephen P., SVP & CFO of ANI Pharmaceuticals Inc, sold 7,312 shares via 2 separate transactions on 2026-03-05, realizing $552,031.04 at a blended average price of $75.50, reducing holdings from 192.9K to 185.5K shares (-3.8%). The stock currently trades at $75.60, down 5.4% over 30 days and 7.6% over 90 days, having declined 23.5% from its 52-week high of $98.81. At the same ticker (ANIP), the insider's prior 3 sales showed mixed timing outcomes: the most recent sale on 2025-08-12 was poorly timed (the stock gained 14.7% in the subsequent 30 days and 3.3% over 90 days), while only 1 of the 3 prior ANIP sales was well-timed at the 90-day mark. The company maintains solid fundamentals—43.8% annual revenue growth, $227.8M quarterly revenue, $26.6M net income, P/E of 13.43, and $1.8B market cap—providing no obvious fundamental distress signal accompanying this divestiture.

SVP Chad Gassert sold 14,736 shares at avg $89.06; all 5 prior ANIP sales were well-timed at 90d mark

Chad Gassert, SVP of Corporate Development & Strategy, executed 2 separate sales totaling 14,736 shares for $1,312,434.94 (blended average $89.06) on 2025-11-12 and 2025-11-13, reducing his holdings by 8.5% to 158,490 shares. His timing pattern at ANI Pharmaceuticals is notable: all 5 of his prior sales at this ticker were well-timed at the 90-day mark, with negative 90-day returns following each sale—indicating he has consistently sold before subsequent declines. The stock is currently -15.0% from its 52-week high and -6.8% over the past 30 days, trading at $84.02. Given his demonstrated track record of well-timed exits at this specific ticker and the company's current elevated valuation (P/E 50.61, market cap $2.1B), his sustained pattern of selling deserves investor scrutiny.

COO-Novitium Ops Shanmugam Muthusamy sold 100,000 shares (18.8% of holdings) for $9.0M at $90.36 avg on Aug 20-21

Shanmugam Muthusamy, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, executed 2 separate sales totaling 100,000 shares for $9,036,007.96 at a blended average price of $90.36, reducing his holdings by 18.8% to 431,920 shares post-transaction. The timing is noteworthy: the current price of $91.01 is -0.1% from the 52-week high of $91.14, and the stock has gained 36.0% over the prior 30 days and 57.5% over the prior 90 days. Across Muthusamy's same-ticker history at ANIP, his 3 prior measurable sales (July 2024) all delivered negative 90-day returns ranging from -5.0% to -9.8%, and his cross-ticker track record shows a 77.78% well-timed sell rate with an average 90-day return of -4.0%. The sale occurs near the stock's all-time recent highs, against a backdrop of strong recent momentum, suggesting the insider is liquidating a material portion of his stake during an elevated valuation window.

Director Thoma Jeanne sold 21,540 shares ($1.9M) at $89.15 blended average; stock near 52-week high $90.62 after 58.2% surge in 90 days.

Director Thoma Jeanne executed two separate sales totaling 21,540 shares for $1,920,369.65 on 2025-08-18, reducing her stake by 47.9% from 44,945 to 23,405 shares. The sales occurred at a blended average price of $89.15, just $1.47 below the current market price of $90.62, which represents the 52-week high. The stock has appreciated 58.2% over the prior 90 days and 38.5% in the last 30 days, positioning this sale near the top of a strong recent rally. While the company shows recent positive momentum with 26.2% annual revenue growth and profitability in the latest quarter, full-year results remain negative, creating mixed fundamentals underneath this near-peak pricing. The scale of the reduction—nearly half of her holdings—alongside the timing at or near recent highs warrants investor scrutiny of board confidence and capital allocation intent.

COO Shanmugam Muthusamy sold 100,000 shares (15.8% of holdings) for $8.8M at $88.25 avg, stock at 52-week high; mixed timing pattern at this ticker

Shanmugam Muthusamy, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, executed two separate sales totaling 100,000 shares for $8,824,533.30 on consecutive days (August 14–15, 2025), reducing his position by 15.8% from 631,920 to 531,920 shares. The sales occurred when the stock was trading at the upper edge of its 52-week range ($89.48–$87.15 transaction prices vs. $53.35–$90.00 range), within 0.3% of the 52-week high. At the same-ticker level, Muthusamy's prior 5 trades at ANIP show 3 of 5 were well-timed at the 90-day mark, but the two most recent (June 2024) posted positive 90-day returns (+2.5%, +2.0%), suggesting the stock rallied after those sales. The current trade's timing remains to be assessed, but the pattern of mixed outcomes at this specific ticker (neither consistently well- nor poorly timed) warrants observation against upcoming price action and company performance as ANIP reported full-year unprofitability despite latest-quarter revenue of $211.4M and 26.2% annual growth.

SVP Chad Gassert sold 20,000 ANIP shares at $86.97 (total $1.7M); stock now 0.3% below 52-week high after surging +47.9% in 90 days.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares at $86.97 on August 15, reducing his holdings by 10.4%. The sale occurred near the 52-week high ($90.00), with the stock trading just -0.3% below that peak and having rallied +47.9% over the prior 90 days. His prior 5 trades at ANIP show 4 of 5 were well-timed at the 90-day mark, suggesting a track record of selling before downturns at this specific ticker. However, context matters: ANI delivered +26.2% annual revenue growth and $8.5M net income on $211.4M quarterly revenue, though the company was unprofitable on a full-year basis, indicating operational instability. The timing—a substantial insider sale near all-time highs after a steep rally—warrants attention to whether management sees valuation stretched relative to underlying financial performance.

CEO Lalwani sold 56,960 shares at $85.93 for $4.9M; stock now at $90.00. His prior ANIP sales: 4 of 5 well-timed at 90d.

Lalwani sold 56,960 shares (-12.2% of holdings) at $85.93 while the stock has since risen to $90.00 (+0.0% from its 52-week high, +40.6% over 30 days, +50.0% over 90 days). Notably, this sale occurred near the 52-week peak. Looking at his same-ticker history at ANIP, 4 of 5 prior sells showed negative 90-day returns, indicating a strong pattern of selling before declines. However, that pattern does not guarantee future timing accuracy, especially given the stock's recent sharp momentum gains. Importantly, the company posted annual revenue growth of +26.2% and recovered to profitability in the latest quarter ($8.5M net income), though it was unprofitable over the most recent full fiscal year—a mixed fundamental backdrop that may have influenced this large CEO disposition.

ANIP CFO Carey Stephen P. sold 50,000 shares at $86.07; stock now at $90.00; prior timing pattern mixed (50% well-timed rate).

CFO Carey Stephen P. sold 50,000 shares (180.9K post-transaction holdings, down 21.7%) at $86.07 on 2025-08-12, with the stock now trading at the 52-week high of $90.00 (+0.0% from peak). The timing context is nuanced: across his cross-ticker track record, his prior 2 sells showed an average 90-day return of -6.6% with a 50.00% well-timed rate (1 of 2 prior sells were well-timed at the 90-day mark), but at ANIP specifically, his 2 prior sales on 2024-03-11 and 2023-08-14 yielded mixed 90-day returns of +1.8% and -15.0% respectively (50% well-timed at this ticker). The fundamental backdrop shows revenue of $211,371,000.00 (quarterly), +26.2% annual growth, but the company was unprofitable over its most recent full fiscal year, suggesting profitability challenges despite revenue momentum. The sale occurs after a significant 30-day rally of +40.6% and 90-day surge of +50.0%, positioning the insider's execution at or near the recent valuation peak.